Viyash Scientific Limited (BOM:512529)
250.15
-6.70 (-2.61%)
At close: May 27, 2026
Viyash Scientific Revenue
In the fiscal year ending March 31, 2026, Viyash Scientific had annual revenue of 34.20B INR with 120.47% growth. Viyash Scientific had revenue of 9.20B in the quarter ending March 31, 2026, with 129.02% growth.
Revenue
34.20B
Revenue Growth
+120.47%
P/S Ratio
3.28
Revenue / Employee
27.49M
Employees
1,244
Market Cap
112.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 34.20B | 18.69B | 120.47% |
| Mar 31, 2025 | 15.51B | 1.82B | 13.26% |
| Mar 31, 2024 | 13.70B | -511.78M | -3.60% |
| Mar 31, 2023 | 14.21B | 80.93M | 0.57% |
| Mar 31, 2022 | 14.13B | 512.01M | 3.76% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 83.46B |
| Granules India | 53.66B |
| J. B. Chemicals & Pharmaceuticals | 41.93B |
| Caplin Point Laboratories | 21.87B |
| AstraZeneca Pharma India | 21.77B |
| FDC Limited | 20.78B |
| Sanofi India | 17.74B |
| Rubicon Research | 15.98B |
Viyash Scientific News
- 6 months ago - SeQuent Scientific shares jump over 10% as NCLT approves merger with Viyash Lifesciences - Business Upturn
- 1 year ago - Sequent Scientific Q4 Results: Revenue up 11% YoY to Rs 401 crore - Business Upturn
- 1 year ago - Sequent Scientific Q3 FY25 results: Revenue up 18.7% YoY to Rs 390.8 crore, Net profit declines 58.5% YoY - Business Upturn
- 1 year ago - India's Animal Healthcare Industry on a High-Growth Trajectory, Projected to Reach USD 2.0 Billion by 2034| Exclusive Report by Transparency Market Research Inc. - Benzinga
- 1 year ago - SeQuent Scientific consolidates ownership of subsidiaries in Sweden and Italy - Business Upturn
- 1 year ago - Sequent Scientific and Viyash Life Sciences announce merger to create animal pharma leader - Business Upturn
- 1 year ago - Sequent Scientific shares surge nearly 9% following merger with Viyash Life Sciences - Business Upturn
- 1 year ago - SeQuent Scientific hits 52-week high, surges nearly 9% in 20 minutes - Business Upturn